Complement Therapeutics

United Kingdom - London

• 18/04/2023
• Series A
• $78,929,000

Complement Therapeutics (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.

Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions.

The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.

Related People

Rafiq HasanFounder

United Kingdom - West Ealing, England

Proven track record of leading global cross-functional commercial teams to deliver year on year sales growth, managing multi-billion dollar global franchises. A unique combination of in-depth commercial, medical, market access and P&L experience. Passionate about medtech and innovation, mentoring start-ups at Wayra and through the UK Clinical Entrepreneurship Programme.

LinkedIn https://www.linkedin.com/in/rafiqhasan/